Medicare Enrolled

Dr. Gwendoline Menga, DO

Rheumatology · Conroe, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
3068 COLLEGE PARK DR STE A, Conroe, TX 77384
8328215550
In practice since 2009 (17 years)
NPI: 1447496047 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Menga from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Menga? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Menga

Dr. Gwendoline Menga is a rheumatology in Conroe, TX, with 17 years in practice. Based on federal Medicare data, Dr. Menga performed 283,141 Medicare services across 1,226 unique beneficiaries.

Between the years covered by Open Payments, Dr. Menga received a total of $25,140 from 50 pharmaceutical and/or device companies across 1283 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Menga is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 17 years in practice▲ Top 1% volume in TX$ $25,140 industry payments

Medicare Practice Summary

Medicare Utilization ↗
283,141
Medicare services
Top 1% in TX for rheumatology
1,226
Unique beneficiaries
$6
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~16,655 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Certolizumab injection (Cimzia)227,200$4$20
Romosozumab injection (Evenity) for osteoporosis21,000$8$26
Golimumab infusion (Simponi Aria)17,820$10$55
Abatacept infusion (Orencia)8,900$34$131
Denosumab injection (Prolia/Xgeva)4,140$18$46
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle1,204$56$152
Office visit, established patient (30-39 min)632$88$213
Injection, ketorolac tromethamine, per 15 mg475$0$15
Drug injection, under skin or into muscle449$11$33
Administration of chemotherapy into vein, 1 hour or less267$100$350
Infusion, normal saline solution, 250 cc259$1$20
Injection, methylprednisolone acetate, 80 mg201$9$26
Administration of chemotherapy into vein, each additional hour152$22$75
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less124$48$138
Office visit, established patient (20-29 min)121$66$145
New patient office visit (45-59 min)73$117$322
Injection, zoledronic acid, 1 mg70$6$26
Joint injection, major joint54$55$140
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
9.6% high complexity
90.1% medium
0.3% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$25,140
Total received (2018-2024)
Avg $3,591/year across 7 years
Top 16% in TX for rheumatology
50
Companies
1,283
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$22,648 (90.1%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$2,481 (9.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$11 (0.0%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$5,925
2023
$3,726
2022
$2,949
2021
$2,520
2020
$2,609
2019
$3,720
2018
$3,690

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Amgen Inc.
$4,552
Janssen Biotech, Inc.
$3,756
PFIZER INC.
$2,123
UCB, Inc.
$2,072
ABBVIE INC.
$1,469
Novartis Pharmaceuticals Corporation
$1,429
Lilly USA, LLC
$1,268
GlaxoSmithKline, LLC.
$973
E.R. Squibb & Sons, L.L.C.
$789
Mallinckrodt Hospital Products Inc.
$664
GENZYME CORPORATION
$631
AbbVie, Inc.
$597
Radius Health, Inc.
$552
AbbVie Inc.
$545
AstraZeneca Pharmaceuticals LP
$510
Genentech USA, Inc.
$472
Celgene Corporation
$365
Organon Llc
$240
Janssen Scientific Affairs, LLC
$223
Organon LLC
$206
Johnson & Johnson Health Care Systems Inc.
$150
Antares Pharma, Inc.
$145
Alexion Pharmaceuticals, Inc.
$141
Boehringer Ingelheim Pharmaceuticals, Inc.
$131
Sandoz Inc.
$119
Horizon Therapeutics plc
$109
Hikma Pharmaceuticals USA
$106
Horizon Pharma plc
$91
Abbott Laboratories
$81
Ultragenyx Pharmaceutical Inc.
$60
Aurinia Pharma U.S., Inc.
$58
Kiniksa Pharmaceuticals, Ltd.
$54
ANI Pharmaceuticals, Inc.
$54
Iroko Pharmaceuticals, LLC
$53
TerSera Therapeutics LLC
$48
MEDEXUS PHARMA, INC.
$42
Kiniksa Pharmaceuticals International, plc
$28
MEDAC PHARMA, INC.
$27
Teva Pharmaceuticals USA, Inc.
$27
Mallinckrodt Enterprises LLC
$22
Kyowa Kirin, Inc.
$19
Mylan Institutional Inc.
$18
Exeltis, USA Inc.
$18
Gilead Sciences, Inc.
$17
Merck Sharp & Dohme Corporation
$17
Sobi, Inc
$17
West-Ward Pharmaceuticals
$16
Bioventus LLC
$15
Cumberland Pharmaceuticals, Inc.
$13
Janssen Pharmaceuticals, Inc
$11
Top 3 companies account for 41.5% of total payments
Associated products mentioned in payments ›
ACTHAR · AMJEVITA · AVSOLA · AXIUM · Actemra · Arcalyst · BENLYSTA · Bimzelx · COSENTYX · CYLTEZO · Cimzia · Crysvita · EVENITY · Enbrel · FORTEO · GELSYN 3 · GRANIX · HADLIMA · HUMIRA · HYRIMOZ · Humira · INFLECTRA · KEVZARA · KRYSTEXXA · Kineret · LUPKYNIS · LYRICA · Mitigare · OFEV · ORENCIA · OTREXUP · Otezla · Otrexup · PENNSAID · PURIFIED CORTROPHIN GEL · Proclaim Family of SCS IPGs · Proclaim IPG · Prolia · Quzyttir · RAYOS · REDITREX · REMICADE · RENFLEXIS · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SIMPONI · SIMPONI ARIA · SKYRIZI · STELARA · STRENSIQ · Strensiq · TALTZ · TAVNEOS · TREMFYA · Tavneos · Tymlos · VIVLODEX · XELJANZ · ZORVOLEX
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (90%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $9 per 100 Medicare services performed
Looking for a rheumatology in Conroe?
Compare rheumatologys in the Conroe area by procedure volume, costs, and industry payment transparency.
Browse rheumatologys nearby

Geographic Context

Rheumatologys within 10 mi
28
Per 100K population
4.3
County median income
$97,266
Nearest hospital
ST LUKE'S THE WOODLANDS HOSPITAL
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Menga is a mixed practice specialist, with above-average Medicare volume (top 1% in TX), and high industry engagement (low-engagement, top 16%), with 17 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Menga experienced with certolizumab injection (cimzia)?
Based on Medicare claims data, Dr. Menga performed 227,200 certolizumab injection (cimzia) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Menga receive payments from pharmaceutical companies?
Yes. Dr. Menga received a total of $25,140 from 50 companies across 1,283 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Menga's costs compare to other rheumatologys in Conroe?
Dr. Menga's average Medicare payment per service is $6. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Menga) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →